Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

被引：5

作者：

Lodise, Thomas ^{[1
]}

Colman, Sam ^{[2
]}

Stein, Daniel S. ^{[3
]}

Fitts, David ^{[3
]}

Goldberg, Lisa ^{[3
]}

Alexander, Elizabeth ^{[3
]}

Scoble, Patrick J. ^{[3
]}

Schranz, Jennifer ^{[3
]}

机构：

[1] Albany Coll Pharm & Hlth Sci, 108 New Scotland Ave, Albany, NY 12208 USA

[2] Covance Market Access Serv Inc, Gaithersburg, MD USA

[3] Nabriva Therapeut US Inc, King Of Prussia, PA USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2020年 / 7卷 / 05期

关键词：

community-acquired bacterial pneumonia; fluoroquinolones; lefamulin; patient discharge; time to clinical response; DISCHARGE; RISK; CEFTRIAXONE; MANAGEMENT; STABILITY; OUTCOMES; RULE;

D O I：

10.1093/ofid/ofaa145

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Time to clinical response, a proxy for hospital "discharge readiness," was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical response (4 days) was observed in both treatment groups.

引用

页数：4

共 19 条

[1] Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
Lodise, Thomas P.
Colman, Sam
Alexander, Elizabeth
Stein, Daniel S.
Fitts, David
Goldberg, Lisa
Schranz, Jennifer
OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (06):
[2] EFFICACY OF LEFAMULIN VS MOXIFLOXACIN IN ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA: RESULTS OF THE LEFAMULIN EVALUATION AGAINST PNEUMONIA (LEAP) 1 AND LEAP 2 DOUBLE-BLIND NONINFERIORITY PHASE-3 CLINICAL TRIALS
Sandrock, Christian
Schranz, Jennifer
Goldberg, Lisa
Alexander, Elizabeth
Moran, Gregory
Shorr, Andrew
Gelone, Steven
CHEST, 2019, 156 (04) : 418A - 419A
[3] SAFETY AND TOLERABILITY OF LEFAMULIN VS MOXIFLOXACIN IN ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA: RESULTS OF THE LEFAMULIN EVALUATION AGAINST PNEUMONIA (LEAP) 1 AND LEAP 2 DOUBLE-BLIND NONINFERIORITY PHASE-3 CLINICAL TRIALS
Sandrock, Christian
Schranz, Jennifer
Goldberg, Lisa
Alexander, Elizabeth
Moran, Gregory
Shorr, Andrew
Gelone, Steven
CHEST, 2019, 156 (04) : 1127A - 1128A
[4] Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial
Alexander, Elizabeth
Goldberg, Lisa
Das, Anita F.
Moran, Gregory J.
Sandrock, Christian
Gasink, Leanne B.
Spera, Patricia
Sweeney, Carolyn
Paukner, Susanne
Wicha, Wolfgang W.
Gelone, Steven P.
Schranz, Jennifer
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (17): : 1661 - 1671
[5] Assessment of Time to Clinical Response, a Proxy for Discharge Readiness, among Hospitalized Patients with Community-Acquired Pneumonia Who Received either Ceftaroline Fosamil or Ceftriaxone in Two Phase III FOCUS Trials
Lodise, Thomas P.
Anzueto, Antonio R.
Weber, David J.
Shorr, Andrew F.
Yang, Min
Smith, Alexander
Zhao, Qi
Huang, Xingyue
File, Thomas M.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (02) : 1119 - 1126
[6] EFFICACY AND SAFETY OF LEFAMULIN VS MOXIFLOXACIN FOR ATYPICAL RESPIRATORY PATHOGENS IN ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA: POOLED RESULTS FROM THE LEFAMULIN EVALUATION AGAINST PNEUMONIA (LEAP) 1 AND LEAP 2 DOUBLE-BLIND NONINFERIORITY PHASE-3 CLINICAL TRIALS
Shorr, Andrew
Schranz, Jennifer
Goldberg, Lisa
Paukner, Susanne
Alexander, Elizabeth
Moran, Gregory
Sandrock, Christian
Gelone, Steven
CHEST, 2019, 156 (04) : 1133A - 1134A
[7] Hospitalization rates among patients with community-acquired pneumonia treated with telithromycin vs clarithromycin: results from two randomized, double-blind, clinical trials
Niederman, MS
Chang, JR
Stewart, J
Asche, CV
Lavin, B
Nusrat, R
Sullivan, SD
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (07) : 969 - 980
[8] Health-Related Quality of Life as Measured by the 36-Item Short Form Survey Among Adults With Acute Bacterial Skin and Skin Structure Infections who Received Either Omadacycline or Linezolid in a Phase 3 Double-Blind, Double-Dummy Clinical Trial
Chitra, Surya
Hinahara, Jordan
Goss, Thomas F.
Gunter, Kyle
LaPensee, Kenneth
OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (10):
[9] Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial
Yuan, Jinyi
Mo, Biwen
Ma, Zhuang
Lv, Yuan
Cheng, Shih-Lung
Yang, Yanping
Tong, Zhaohui
Wu, Renguang
Sun, Shenghua
Cao, Zhaolong
Wu, Jufang
Zhu, Demei
Chang, Liwen
Zhang, Yingyuan
Zhao, Li
Wang, Xiongbiao
Wang, Xuefen
Wang, Dexi
Li, Xiangyang
Peng, Yiqiang
Liang, Yongjie
Liu, Hua
Xiao, Zuke
Lv, Xiaoju
Wu, Shiman
Dai, Yuanrong
Huang, Yijiang
Hu, Zhenghong
Qiu, Chen
Li, Xi
Zhang, Suiyang
Li, Wenpu
Liu, Shuang
Shi, Yi
Xiong, Chang
Kuang, Jiulong
Xiu, Qingyu
Cui, Shehuai
Li, Jianguo
Lin, Qichang
Huang, Wenxiang
Wan, Yixin
Li, Qimangu
Shen, Ce
Xiao, Yi
Wu, Xiaoju
Chuang, Yin Ching
Perng, Wann Cherng
Tsao, Shih-Ming
Hsu, Jeng-Yuan
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2019, 52 (01) : 35 - 44
[10] A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients
Li, Ying
Zhu, Demei
Sun, Shenghua
Chang, Xiaoyue
Cao, Zhaolong
Yang, Yanping
Fu, Xiuhua
Li, Xiangyang
Xu, Jinfu
Zhu, Yingqun
Hui, Fuxin
Xu, Xingxiang
Chen, Zhang
Peng, Liping
Ma, Zhuang
Mo, Biwen
Li, Chen
Lv, Yuan
Zhao, Li
Zhu, Guangfa
He, Yong
Liu, Hua
Chen, Jichao
Wang, Ying
Liang, Yongjie
Lu, Youjin
Qin, Zhiqiang
Yang, Hongzhong
Zhang, Min
Wu, Shiman
Tong, Zhaohui
Ye, Feng
Xiao, Zuke
Wang, Xuefen
Qiu, Chen
Kuang, Jiulong
Huang, Huaping
Wang, Kai
Ying, Kejing
Jin, Faguang
Lv, Xiaoju
Huang, Yijiang
Liu, Deling
Wang, Wei
Zhang, Yingyuan
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 64 (02)

← 1 2 →